Primary progressive apraxia of speech
Methodology & AI Transparency ⓘ
Primary progressive apraxia of speech Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Primary progressive apraxia of speech—coded clinically as G31.87 across Memory & Cognition guidelines—combines volumetric brain MRI [Primary progressive apraxia of speech G31.87] with structured follow-up of Homocysteine & Vitamin in Primary progressive apraxia of speech (G31.87: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.87)).
- 2 Real-world patient consensus: Diagnostic registry G31.87: Primary progressive apraxia of speech is managed within Memory & Cognition.
- 3 Typical cash cost range: Primary evaluation for Primary progressive apraxia of speech incorporates volumetric brain MRI [Primary progressive apraxia of speech G31.87] and symptom diary review.
- 4 Top reported side effects / signs: Key Memory & Cognition biomarkers for Primary progressive apraxia of speech (G31.87): MoCA Cognitive Screening in Primary progressive apraxia of speech (G31.87: Score) & Homocysteine & Vitamin in Primary progressive apraxia of speech (G31.87: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.87)).
Ask our AI Specialists anything about Primary progressive apraxia of speech
What Is Primary progressive apraxia of speech?
Primary progressive apraxia of speech—coded clinically as G31.87 across Memory & Cognition guidelines—combines volumetric brain MRI [Primary progressive apraxia of speech G31.87] with structured follow-up of Homocysteine & Vitamin in Primary progressive apraxia of speech (G31.87: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.87)).
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Primary progressive apraxia of speech (G31.87, Memory & Cognition) reflects neurovascular unit dysfunction [Primary progressive apraxia of speech G31.87]. longitudinal control is benchmarked via MoCA Cognitive Screening in Primary progressive apraxia of speech (G31.87: Score).
Common Symptoms & Clinical Signs
- • Presentation of Primary progressive apraxia of speech (G31.87): word-finding pauses, difficulty in Primary progressive apraxia of speech (G31.87: managing multi-step finances,)
- • Secondary Primary progressive apraxia of speech clinical sign: subtle personality shifts, in Primary progressive apraxia of speech (G31.87: apathy, or evening)
- • Symptom flares in Primary progressive apraxia of speech correlating with MoCA Cognitive Screening in Primary progressive apraxia of speech (G31.87: Score) deviation outside >= 26 / 30 (G31.87)
- • Functional memory & cognition impact requiring volumetric brain MRI [Primary progressive apraxia of speech G31.87] evaluation (G31.87)
Primary progressive apraxia of speech Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G31.87 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Primary progressive apraxia of speech (G31.87: Score) | >= 26 / 30 (G31.87) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Primary progressive apraxia of speech (G31.87: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.87) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Primary progressive apraxia of speech (G31.87: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G31.87) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Primary progressive apraxia of speech
Treatment selection for Primary progressive apraxia of speech depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Primary progressive apraxia of speech)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| 7 Questions to Bring to Your Next Doctor Visit (And Why They Work) Patients who bring a simple written list of 5 to 7 focused questions get clearer answers, leave with fewer medication mix-ups, and feel far more confident about their care plan—without making the appointment run longer. BMJ Quality & Safety / Patient Education and Counseling • 2026-11-01 • Systematic Review | N = 4,820 | 96/100 | PMID 34582101 ↗ |
| New Insights on Modeling Statin-Induced Reductions of heart and blood vessel Events in Primary: What a 6,735-Participant Study Found Our results show that, in individuals without clinical ASCVD, statin therapy has the potential to reduce the frequency of CV events. Cardiology • 2018-01-15 • Meta-Analysis | N = 6,735 | 94/100 | PMID 29705799 ↗ |
| New Insights on Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary: What a 628-Participant Study Found Ezetimibe plus atorvastatin was well tolerated, with a safety profile similar to atorvastatin alone and to placebo. Circulation • 2003-05-20 • Randomized Controlled Trial | N = 628 | 93/100 | PMID 12719279 ↗ |
| New Insights on Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in: What a 555-Participant Study Found Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Arthritis & rheumatology (Hoboken, N.J.) • 2021-01-15 • Phase III Randomized Trial | N = 555 | 93/100 | PMID 32770640 ↗ |
| New Insights on A phase 3, multicenter, randomized, gold-standard blind, vehicle-controlled,: What a 281-Participant Study Found In the sofpironium group, common events (incidence, ≥5%) were nasopharyngitis (14.2%) and dermatitis/skin redness at the application site (8.5%/5.7%), with no serious side effects reported. The Journal of dermatology • 2021-03-15 • Phase III Randomized Trial | N = 281 | 93/100 | PMID 33410265 ↗ |
Primary progressive apraxia of speech Patient Community & “People Like Me” Threads
Filter Primary progressive apraxia of speech community threads and patient logs by age, biological sex, dosage, and treatment duration.